Log In
BCIQ
Print this Print this
 

AlloVax

  Manage Alerts
Collapse Summary General Information
Company Immunovative Therapies Ltd.
DescriptionIndividualized cancer vaccine using AlloStim technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationHead and neck cancer
Indication DetailsTreat metastatic squamous cell cancer of the head and neck (SCCHN)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$10.0M

$0.5M

$9.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/15/2011

$10.0M

$0.5M

$9.5M

Get a free BioCentury trial today